Literature DB >> 16498938

FDG-PET on irradiated brain tumor: ten years' summary.

S X Wang1, J Boethius, K Ericson.   

Abstract

PURPOSE: To evaluate FDG-PET in post-radiotherapy differentiation of tumor recurrence/malignant degeneration and radiation reaction, and to assess the role of PET in terms of survival.
MATERIAL AND METHODS: 117 consecutive patients with a total of 156 FDG-PET examinations with positive but non-diagnostic MRI and/or CT were included. Final diagnosis was based on histopathology or correlated with radiologic and clinical follow-up. Brain metastases from lung carcinomas were further studied separately. Survival time was analysed using the Kaplan-Meier method.
RESULTS: There were 61 true-positive, 2 false-positive, 15 false-negative, and 51 true-negative PET examinations; 5 positive and 22 negative PET examinations were indeterminate. The positive predictive value of a PET examination was 96% in all and 100% in brain metastases from lung carcinoma. The negative predictive value based on the histopathologic results was 55.6%. Survival time was significantly longer in patients with negative PET.
CONCLUSION: FDG-PET is a valuable tool in the detection of tumor recurrence, especially lung carcinoma metastasis. FDG uptake is a prognostic marker.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16498938     DOI: 10.1080/02841850500335101

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  17 in total

1.  Support vector machine multiparametric MRI identification of pseudoprogression from tumor recurrence in patients with resected glioblastoma.

Authors:  Xintao Hu; Kelvin K Wong; Geoffrey S Young; Lei Guo; Stephen T Wong
Journal:  J Magn Reson Imaging       Date:  2011-02       Impact factor: 4.813

2.  Perfusion-metabolism coupling in recurrent gliomas: a prospective validation study with 13N-ammonia and 18F-fluorodeoxyglucose PET/CT.

Authors:  Bangkim Chandra Khangembam; Sellam Karunanithi; Punit Sharma; Sudhir Suman Kc; Rajeev Kumar; Pramod Kumar Julka; Rakesh Kumar; Chandrasekhar Bal
Journal:  Neuroradiology       Date:  2014-07-03       Impact factor: 2.804

3.  Comparison of proton magnetic resonance spectroscopy with fluorine-18 2-fluoro-deoxyglucose positron emission tomography for assessment of brain tumor progression.

Authors:  Farzin Imani; Fernando E Boada; Frank S Lieberman; Denise K Davis; Erin L Deeb; James M Mountz
Journal:  J Neuroimaging       Date:  2010-12-14       Impact factor: 2.486

4.  Prognostic significance of parameters derived from co-registered 18F-fluorodeoxyglucose PET and contrast-enhanced MRI in patients with high-grade glioma.

Authors:  M J Paldino; T Z Wong; D A Reardon; H S Friedman; D P Barboriak
Journal:  Br J Radiol       Date:  2010-10-19       Impact factor: 3.039

5.  Molecular and metabolic pattern classification for detection of brain glioma progression.

Authors:  Farzin Imani; Fernando E Boada; Frank S Lieberman; Denise K Davis; James M Mountz
Journal:  Eur J Radiol       Date:  2013-11-20       Impact factor: 3.528

6.  Evaluation of fluoride-labeled boronophenylalanine-PET imaging for the study of radiation effects in patients with glioblastomas.

Authors:  Minoru Miyashita; Shin-Ichi Miyatake; Yoshio Imahori; Kunio Yokoyama; Shinji Kawabata; Yoshinaga Kajimoto; Masa-Aki Shibata; Yoshinori Otsuki; Mitsunori Kirihata; Koji Ono; Toshihiko Kuroiwa
Journal:  J Neurooncol       Date:  2008-06-20       Impact factor: 4.130

7.  Distinction between glioma progression and post-radiation change by combined physiologic MR imaging.

Authors:  Eiji Matsusue; James R Fink; Jason K Rockhill; Toshihide Ogawa; Kenneth R Maravilla
Journal:  Neuroradiology       Date:  2009-10-16       Impact factor: 2.804

8.  Functional brain imaging: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2006-12-01

9.  NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies.

Authors:  Alexander M Spence; Mark Muzi; Jeanne M Link; Finbarr O'Sullivan; Janet F Eary; John M Hoffman; Lalitha K Shankar; Kenneth A Krohn
Journal:  Mol Imaging Biol       Date:  2009-03-27       Impact factor: 3.488

10.  Evaluation of dynamic contrast-enhanced T1-weighted perfusion MRI in the differentiation of tumor recurrence from radiation necrosis.

Authors:  Vibeke A Larsen; Helle J Simonsen; Ian Law; Henrik B W Larsson; Adam E Hansen
Journal:  Neuroradiology       Date:  2012-12-22       Impact factor: 2.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.